Can Abbott Laboratories (ABT)’s Instinct Sensor Give MiniMed Group (MMED) a Competitive Edge?

MiniMed Group, Inc. (MMED) and Abbott Laboratories (ABT) have partnered in August to integrate Abbott's Instinct continuous glucose sensor with MiniMed's MiniMed Flex system. This collaboration aims to give MiniMed an edge in the diabetes technology market. The MiniMed Flex system offers app-controlled automated insulin delivery and features SmartGuard technology and Meal Detection automation.

It has a 300-unit insulin capacity, a 7-day Extended infusion set, and has demonstrated a 80% Time in Range with over 90% overnight real-world data.

However, MiniMed is a specialized pure-play diabetes technology company with a market cap of $5.67 billion, while Abbott is a healthcare powerhouse with a significantly larger market cap of $12.6 billion. Abbott reported $12.6 billion in Q2 2026 revenue, a 13.0% growth rate, and $1.31 in adjusted EPS. MiniMed's fiscal Q1 2027 results are due on September 1, 2026.

The partnership targets market share gains for MiniMed through the MiniMed Flex launch and solves a historical weakness in sensor ergonomics. The financial outlook for Abbott remains strong, with its broad diversification across diagnostics, nutrition, and medical devices helping insulate it from single-product headwinds.